CYCLACEL PHARMACEUTICALS
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
CYCLACEL PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Berkeley Heights, New Jersey, United States
Country:
United States
Website Url:
http://www.cyclacel.com
Total Employee:
11+
Status:
Active
Contact:
+1 (908) 517 7330
Email Addresses:
[email protected]
Total Funding:
166.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Domain Not Resolving
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Avid Radiopharmaceuticals
Avid Radiopharmaceuticals develops molecular imaging agents for detecting and monitoring chronic human diseases.
Cognition Therapeutics
Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
TARIS Biomedical
TARIS Biomedical is a pharmaceutical company developing therapies for genitourinary system issues.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Scottish Equity Partners
Scottish Equity Partners investment in Venture Round - Cyclacel Pharmaceuticals
Quest for Growth
Quest for Growth investment in Series D - Cyclacel Pharmaceuticals
Merifin Capital
Merifin Capital investment in Series D - Cyclacel Pharmaceuticals
UOB Venture
UOB Venture investment in Series D - Cyclacel Pharmaceuticals
Excalibur Fund Managers
Excalibur Fund Managers investment in Series D - Cyclacel Pharmaceuticals
D.C. Thomson & Co.
D.C. Thomson & Co. investment in Series D - Cyclacel Pharmaceuticals
Societe Generale Asset Management
Societe Generale Asset Management investment in Series D - Cyclacel Pharmaceuticals
Temasek Holdings
Temasek Holdings investment in Series D - Cyclacel Pharmaceuticals
HBM Partners
HBM Partners investment in Series D - Cyclacel Pharmaceuticals
Scottish Equity Partners
Scottish Equity Partners investment in Series D - Cyclacel Pharmaceuticals
Official Site Inspections
http://www.cyclacel.com Semrush global rank: 4.95 M Semrush visits lastest month: 1.72 K
- Host name: 66-135-21-102.constant.com
- IP address: 66.135.21.102
- Location: Salt Lake City United States
- Latitude: 40.6487
- Longitude: -111.9682
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84129
More informations about "Cyclacel Pharmaceuticals"
Cyclacel Pharmaceuticals, Inc. - Harnessing …
Nov 14, 2024 Cyclacel is a pioneer in the field of cell cycle biology to treat cancer. We use insights in cancer biology to research and develop medicines that address the growing …See details»
About Us | Cyclacel Pharmaceuticals, Inc.
McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, …See details»
Cyclacel - Wikipedia
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Berkeley Heights, New Jersey and Dundee, Scotland, developing cancer treatments. Cyclacel was founded in 1996 by David Lane, PhD. See details»
Cyclacel Pharmaceuticals - Crunchbase Company …
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized …See details»
Cyclacel Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The …
View Cyclacel Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. ... The Org helps you hire …See details»
Org Chart Cyclacel Pharmaceuticals - The Official Board
Organizational Chart of Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals www.cyclacel.com +1 908 517 7330; Add an executive. Cyclacel Pharmaceuticals News . Anything missing? We …See details»
Corporate Governance - Cyclacel Pharmaceuticals, Inc.
Cyclacel is committed to maintaining high ethical standards in its business operations. The following documents describe these standards and the internal policies we have established to …See details»
Governance Cyclacel Pharmaceuticals, Inc. - MarketScreener.com
Nov 30, 2004 Organization Committee Chair 2024-06-20 Robert Spiegel. 73 year Compensation Committee Chair 2012-07-17 ... Cyclacel Pharmaceuticals, Inc. is a clinical-stage …See details»
Cyclacel Pharmaceuticals Announces Agreement for the …
6 days ago David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO. BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel …See details»
Cyclacel Pharmaceuticals, Inc. - Dun & Bradstreet
Company Description: Cyclacel Pharmaceuticals wants to stop the cycle of disease. The company's main focus is on cancer, but it is also working on treatments for inflammation, type …See details»
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO
Jan 30, 2023 Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The …See details»
Cyclacel Pharmaceuticals - Overview, News & Similar companies ...
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. …See details»
Cyclacel Pharmaceuticals Company Profile - Office Locations ...
Oct 23, 2024 Cyclacel Pharmaceuticals has 4 employees across 2 locations and $420 k in annual revenue in FY 2023. See insights on Cyclacel Pharmaceuticals including office …See details»
Cyclacel Pharmaceuticals Restructures Leadership and …
3 days ago Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, primarily utilizing cell cycle, transcriptional regulation, and mitosis biology. Their key products …See details»
Cyclacel Pharmaceuticals Restructures Leadership and Financial …
3 days ago Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, primarily utilizing cell cycle, transcriptional …See details»
Cyclacel Pharmaceuticals - Funding, Financials, Valuation & Investors
Cyclacel Pharmaceuticals is registered under the ticker NASDAQ:CYCC . Their stock opened with $8.00 in its Mar 28, 2006 IPO. Stock Symbol NASDAQ:CYCC ; Valuation at IPO $118.2M; …See details»
Cyclacel Pharmaceuticals Announces Agreement for the …
5 days ago Cyclacel. David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO. BERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel …See details»
Cyclacel Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
The overall response rate (ORR) was 17% (1/6) and the disease control rate (DCR) was 100% (6/6). About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical …See details»
Pipeline | Cyclacel Pharmaceuticals, Inc.
McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at …See details»
Cyclacel Pharmaceuticals, Inc. (CYCC) Company Profile
Oct 11, 2024 Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United …See details»